Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WTX 124

Next Previous
Drug Profile

WTX 124

Alternative Names: WTX-124

Latest Information Update: 29 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Werewolf Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Dec 2025 WTX 124 is available for licensing as of 18 Dec 2025. https://werewolftx.com/
  • 18 Dec 2025 Werewolf Therapeutics completes an end-of-phase I meeting with the US FDA for registrational pathway of WTX 124 in Melanoma prior to December 2025
  • 18 Dec 2025 Efficacy and adverse events data from a phase I/Ib trial in Solid tumours were released by Werewolf Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top